Experimental neuroprotection in ischemic stroke: a concise review

If this is truly helpful information to survivors writing it in journals like this is worthless, doctors don't seem to keep up with research. Survivors can't easily get to it to train their doctors in the finer points of stroke recovery.  A public database of stroke research is needed.
http://thejns.org/doi/full/10.3171/2017.1.FOCUS16497

• Gary B. Rajah, MD, and
• Yuchuan Ding, MD, PhD

Department of Neurosurgery, University Health Center, Wayne State University, Detroit Michigan

ABBREVIATIONS AIS = acute ischemic stroke; MB = methylene blue; MCA = middle cerebral artery; NMDAR = N-methyl-d-aspartate receptor; Treg = regulatory T cell.

INCLUDE WHEN CITING DOI: 10.3171/2017.1.FOCUS16497.

Correspondence Yuchuan Ding, Department of Neurosurgery, Lande Building, #48, 550 East Canfield, Detroit, MI 48201. email: yding@med.wayne.edu.

Related Articles

By Keywords:

neuroprotection, acute ischemic stroke, free radical, excitotoxicity, immune response

Abstract

Acute ischemic stroke (AIS) is a leading cause of disability and death worldwide. To date, intravenous tissue plasminogen activator and mechanical thrombectomy have been standards of care for AIS. There have been many advances in diagnostic imaging and endovascular devices for AIS; however, most neuroprotective therapies seem to remain largely in the preclinical phase. While many neuroprotective therapies have been identified in experimental models, none are currently used routinely to treat stroke patients. This review seeks to summarize clinical studies pertaining to neuroprotection, as well as the different preclinical neuroprotective therapies, their presumed mechanisms of action, and their future applications in stroke patients.